- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07612436
AI-empowered Nudge to Improve Colonoscopy Uptake (AINC)
AI-empowered Nudge to Improve Colonoscopy Uptake (AINC): A Pragmatic Cluster-Randomized Trial
Colorectal cancer (CRC) ranks third in both incidence and mortality among all malignant tumors in China. Studies have shown that early screening can significantly reduce its incidence and mortality. Colonoscopy is the gold standard for CRC screening; however, compliance with colonoscopy among high-risk groups in China is very low. Artificial intelligence (AI)-assisted tools can provide real-time, personalized health education, and nudge strategies can help translate intent into action. This trial aims to evaluate the effectiveness of AI-empowered nudge for improving colonoscopy uptake among high-risk individuals aged 45 to 74 in China. It's a two-arm, pragmatic cluster randomized controlled trial. The main question it aims to answer is whether the AI-enabled personalized health education and nudge strategies improve colonoscopy adherence.
Participants will:
- Be recruited and allocated into one of two groups according to the assigned clusters. Participants in one group will be invited to receive usual care. In addition to usual care, participants in the other group will receive AI-empowered nudge, featuring an AI chatbot providing real-time personalized responses and a nudge environment with default screening option.
- Have their colonoscopy status checked at the end of trial.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
We will conduct a two-arm, parallel-group, cluster-randomized controlled trial to evaluate the effectiveness of an AI-empowered nudge model in improving colonoscopy uptake (AINC) among high-risk individuals aged 45 to 74. The AI-empowered nudge model combines default screening nudging with an AI chatbot on colorectal cancer screening. We will also evaluate the feasibility of this AINC model, and identify the facilitators and barriers to its real-world adoption.
The colonoscopy uptake rate is approximately 15% in China, and the proposed intervention is expected to increase this rate by 10%. Sample size calculation, based on detecting an increase in colonoscopy uptake from 15% to 25% with 90% power (α=0.05, two-sided), an ICC of 0.05, and 30 clusters per arm, indicates a need for 24 participants per cluster. There are 720 per arm, and 1440 in total. Allowing for 15% attrition, the final sample size is determined to be 1680 from 70 clusters. As a pragmatic trial in real world, the number of participants each cluster depends on the population size of the respective villages or communities. All eligible participants in the participating villages or communities will be included in the study.
Participant recruitment will be conducted across 70 villages/communities in three representative counties/cities in China, covering urban, suburban, and rural areas. Cluster randomisation will be performed at the level of villages or communities using a stratified block design to ensure balanced allocation across the two trial arms. Stratification factors include geographic access to colonoscopy hospital and the size of individuals aged 45 to 74 for each cluster. Clusters with comparable levels of these factors will be grouped into blocks within each city and then randomly assigned within each block to the AINC or control group. The random allocation sequence will be generated by an independent statistician using a computer-based random number generator in R software and implemented via a secure centralised system.
The study procedure involves first identifying high-risk individuals for CRC through an initial risk assessment questionnaire and a fecal immunochemical test (FIT). Those who meet the criteria will then receive the intervention corresponding to their village's assigned study arm. Participants in the intervention group will receive an AI-powered nudge for colonoscopy (AINC), featuring an AI chatbot providing real-time personalized responses and a nudge environment with default screening option, followed by message reminders once per two weeks. The control group will receive usual care. Colonoscopy uptake will be collected via the hospital information system at the 3-month follow-up.
The primary analysis will follow the intention-to-treat (ITT) principle, while the per-protocol (PP) analysis will serve as the secondary analysis. In the ITT analysis, all subjects randomized to each group will be included. Between-group comparisons for continuous and categorical variables will utilize t-tests and chi-square tests. The primary outcome (colonoscopy uptake) will be analyzed using Generalized Estimating Equations (GEE), adjusting for cluster effects and relevant covariates to obtain robust estimates. Covariates include region, age, sex, smoking history, Body Mass Index, history of bowel-related symptoms or diseases, and family history. The timing of colonoscopy uptake will be analyzed using Kaplan-Meier survival curves and log-rank tests, and the intervention effects on the time-to-event will be quantified with a Cox proportional hazards model. Subgroup analyses will be conducted to elucidate the effect heterogeneity across populations stratified by pre-specified characteristics, including region, age, sex, smoking history, Body Mass Index, history of bowel-related symptoms or diseases, and family history.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Zhiyuan Hou, PhD
- Numer telefonu: 86+21 54231112
- E-mail: zyhou@fudan.edu.cn
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Opis
Inclusion Criteria:
- Aged 45-74 years;
- Test positive on the Colorectal Cancer Risk Assessment Scale and the immunochemical fecal occult blood test;
- In good general health, mentally competent;
- Provide informed consent.
Exclusion Criteria:
- History of colorectal resection;
- Previous diagnosis of cancer or currently undergoing any cancer-related treatment;
- Underwent a colonoscopy or sigmoidoscopy within the past 5 years;
- Contraindications to colonoscopy (e.g. severe cardiac, cerebral, lung diseases, or renal dysfunction).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Pojedynczy
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: AI-empowered nudge group
This arm implements a multi-component AI-empowered nudge strategy: Default Appointment: On-site pre-scheduling of colonoscopies for high-risk individuals, providing an "opt-out" mechanism. AI Chatbot: Guided on-site use (≥3 mins) of a dedicated chatbot offering personalized responses on CRC questions to facilitate self-learning. LLM-produced SMS Reminders: For non-adherent participants, ChatGPT-5 generates risk-tailored SMS reminders sent bi-weekly to participants and their families (5 times). |
A digital health education and behavioral nudge intervention.
It utilizes an intelligent chatbot to provide real-time, personalized information about colonoscopy and implements a default screening mechanism to facilitate the translation from screening intention to behavior.
|
|
Aktywny komparator: Control Group
Usual care: Based on the results of the risk assessment questionnaire and FIT test, village doctors will notify the screening results to colorectal cancer high-risk individuals, and instructs recipients to go to the designated hospital for a colonoscopy.
Colonoscopy appointments will be scheduled only for residents who are willing to undergo a colonoscopy.
|
Usual notification of screening results and opt-in appointment for colonoscopy.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Uptake of colonoscopy
Ramy czasowe: Three months after recruitment
|
Defined as whether the participant completes the colonoscopy.
Data will be collected through the Hospital Information System (HIS) using participants' identification.
|
Three months after recruitment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Time to completion of colonoscopy
Ramy czasowe: Three months after recruitment
|
The interval from intervention initiation to the colonoscopy procedure.
Data will be collected from information systems of hospitals.
|
Three months after recruitment
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
User engagement level with intervention
Ramy czasowe: Three months after recruitment
|
Assessed by the issuing number of appointment card and chatbot usage metrics, including usage frequency, interaction duration, and the number of questions asked.
Data will be obtained through backend system logs.
|
Three months after recruitment
|
|
Usability of AI-empowered Nudge Intervention
Ramy czasowe: Three months after recruitment
|
The usability of the intervention will be evaluated using a series of questions on its feasibility, acceptability, and sustainability, as well as the facilitators and barriers of its implementation.
Data will be collected via semi-structured interviews.
|
Three months after recruitment
|
|
Intervention Cost
Ramy czasowe: Three months after recruitment
|
The costs associated with both study arms obtained through work logs, including expenses for doctor manpower, chatbot development, and usage.
Unit of Measure: Chinese Yuan (CNY).
|
Three months after recruitment
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Zhiyuan Hou, PhD, Fudan University
Publikacje i pomocne linki
Publikacje ogólne
- Zhang Q, Wong AKC, Bayuo J. The Role of Chatbots in Enhancing Health Care for Older Adults: A Scoping Review. J Am Med Dir Assoc. 2024 Sep;25(9):105108. doi: 10.1016/j.jamda.2024.105108. Epub 2024 Jun 22.
- Maida M, Mori Y, Fuccio L, Sferrazza S, Vitello A, Facciorusso A, Hassan C. Exploring ChatGPT effectiveness in addressing direct patient queries on colorectal cancer screening. Endosc Int Open. 2025 May 12;13:a25689416. doi: 10.1055/a-2568-9416. eCollection 2025.
- Heald B, Keel E, Marquard J, Burke CA, Kalady MF, Church JM, Liska D, Mankaney G, Hurley K, Eng C. Using chatbots to screen for heritable cancer syndromes in patients undergoing routine colonoscopy. J Med Genet. 2021 Dec;58(12):807-814. doi: 10.1136/jmedgenet-2020-107294. Epub 2020 Nov 9.
- Chen D, Avison K, Alnassar S, Huang RS, Raman S. Medical accuracy of artificial intelligence chatbots in oncology: a scoping review. Oncologist. 2025 Apr 4;30(4):oyaf038. doi: 10.1093/oncolo/oyaf038.
- Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, Cubillos L, Malo T, Reuland DS. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018 Dec 1;178(12):1645-1658. doi: 10.1001/jamainternmed.2018.4637.
- Yu Z, Li B, Zhao S, Du J, Zhang Y, Liu X, Guo Q, Zhou H, He M. Uptake and detection rate of colorectal cancer screening with colonoscopy in China: A population-based, prospective cohort study. Int J Nurs Stud. 2024 May;153:104728. doi: 10.1016/j.ijnurstu.2024.104728. Epub 2024 Feb 20.
- Chen H, Li N, Ren J, Feng X, Lyu Z, Wei L, Li X, Guo L, Zheng Z, Zou S, Zhang Y, Li J, Zhang K, Chen W, Dai M, He J; group of Cancer Screening Program in Urban China (CanSPUC). Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019 Aug;68(8):1450-1457. doi: 10.1136/gutjnl-2018-317124. Epub 2018 Oct 30.
- Chen Y, Zhang Y, Yan Y, Han J, Zhang L, Cheng X, Lu B, Li N, Luo C, Zhou Y, Song K, Iwasaki M, Dai M, Wu D, Chen H. Global colorectal cancer screening programs and coverage rate estimation: an evidence synthesis. J Transl Med. 2025 Jul 22;23(1):811. doi: 10.1186/s12967-025-06887-4.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- Fudan-AINC
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .